Recombinant Virus-like Particles Elicit Protective Immunity Against Avian Influenza A(H7N9) Virus Infection in Ferrets

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2015 Mar 17

PMID 25772674

Citations 37

Authors

Ye V Liu

Michael J Massare

Melissa B Pearce

Xiangjie Sun

Jessica A Belser

Taronna R Maines

Hannah M Creager

Gregory M Glenn

Peter Pushko

Gale E Smith

Terrence M Tumpey

Affiliations

Soon will be listed here.

Abstract

In March 2013, diagnosis of the first reported case of human infection with a novel avian-origin influenza A(H7N9) virus occurred in eastern China. Most human cases have resulted in severe respiratory illness and, in some instances, death. Currently there are no licensed vaccines against H7N9 virus, which continues to cause sporadic human infections. Recombinant virus-like particles (VLPs) have been previously shown to be safe and effective vaccines for influenza. In this study, we evaluated the immunogenicity and protective efficacy of a H7N9 VLP vaccine in the ferret challenge model. Purified recombinant H7N9 VLPs morphologically resembled influenza virions and elicited high-titer serum hemagglutination inhibition (HI) and neutralizing antibodies specific for A/Anhui/1/2013 (H7N9) virus. H7N9 VLP-immunized ferrets subsequently challenged with homologous virus displayed reductions in fever, weight loss, and virus shedding compared to these parameters in unimmunized control ferrets. H7N9 VLP was also effective in protecting against lung and tracheal infection. The addition of either ISCOMATRIX or Matrix-M1 adjuvant improved immunogenicity and protection of the VLP vaccine against H7N9 virus. These results provide support for the development of a safe and effective human VLP vaccine with potent adjuvants against avian influenza H7N9 virus with pandemic potential.

Citing Articles

Advanced technologies for the development of infectious disease vaccines.

Gupta A, Rudra A, Reed K, Langer R, Anderson D Nat Rev Drug Discov. 2024; 23(12):914-938.

PMID: 39433939 DOI: 10.1038/s41573-024-01041-z.

Insect Cell-Based Quadrivalent Seasonal Influenza Virus-like Particles Vaccine Elicits Potent Immune Responses in Mice.

Badruzzaman A, Cheng Y, Sung W, Lee M Vaccines (Basel). 2024; 12(6).

PMID: 38932396 PMC: 11209530. DOI: 10.3390/vaccines12060667.

A Single Vaccination of Chimeric Bivalent Virus-Like Particle Vaccine Confers Protection Against H9N2 and H3N2 Avian Influenza in Commercial Broilers and Allows a Strategy of Differentiating Infected from Vaccinated Animals.

Sun Y, Li Z, Zhang P, Han J, Di H, Qin J Front Immunol. 2022; 13:902515.

PMID: 35874682 PMC: 9304867. DOI: 10.3389/fimmu.2022.902515.

Evaluation of the antigenic stability of influenza virus like particles after exposure to acidic or basic pH.

Kim S, Park Y, Song J Clin Exp Vaccine Res. 2021; 10(3):252-258.

PMID: 34703808 PMC: 8511596. DOI: 10.7774/cevr.2021.10.3.252.

Designing spatial and temporal control of vaccine responses.

Roth G, Picece V, Ou B, Luo W, Pulendran B, Appel E Nat Rev Mater. 2021; 7(3):174-195.

PMID: 34603749 PMC: 8477997. DOI: 10.1038/s41578-021-00372-2.

References

Zeng H, Goldsmith C, Thawatsupha P, Chittaganpitch M, Waicharoen S, Zaki S . Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type i interferon response in polarized human bronchial epithelial cells. J Virol. 2007; 81(22):12439-49. PMC: 2169033. DOI: 10.1128/JVI.01134-07. View

Pushko P, Pearce M, Ahmad A, Tretyakova I, Smith G, Belser J . Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011; 29(35):5911-8. DOI: 10.1016/j.vaccine.2011.06.068. View

Quan F, Vunnava A, Compans R, Kang S . Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010; 5(2):e9161. PMC: 2820088. DOI: 10.1371/journal.pone.0009161. View

Bright R, Carter D, Daniluk S, Toapanta F, Ahmad A, Gavrilov V . Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007; 25(19):3871-8. DOI: 10.1016/j.vaccine.2007.01.106. View

Perrone L, Ahmad A, Veguilla V, Lu X, Smith G, Katz J . Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol. 2009; 83(11):5726-34. PMC: 2681940. DOI: 10.1128/JVI.00207-09. View

Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W . Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368(20):1888-97. DOI: 10.1056/NEJMoa1304459. View

Pushko P, Kort T, Nathan M, Pearce M, Smith G, Tumpey T . Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010; 28(30):4771-6. DOI: 10.1016/j.vaccine.2010.04.093. View

Cox R, Major D, Hauge S, Madhun A, Brokstad K, Kuhne M . A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir Viruses. 2009; 3(3):107-17. PMC: 4634691. DOI: 10.1111/j.1750-2659.2009.00082.x. View

Couch R, Patel S, Wade-Bowers C, Nino D . A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012; 7(12):e49704. PMC: 3519847. DOI: 10.1371/journal.pone.0049704. View

10.

. Emergence of avian influenza A(H7N9) virus causing severe human illness - China, February-April 2013. MMWR Morb Mortal Wkly Rep. 2013; 62(18):366-71. PMC: 4605021. View

11.

Fries L, Smith G, Glenn G . A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013; 369(26):2564-6. DOI: 10.1056/NEJMc1313186. View

12.

Kreijtz J, Wiersma L, de Gruyter H, Vogelzang-van Trierum S, van Amerongen G, Stittelaar K . A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. J Infect Dis. 2014; 211(5):791-800. PMC: 4402375. DOI: 10.1093/infdis/jiu528. View

13.

Ross T, Mahmood K, Crevar C, Schneider-Ohrum K, Heaton P, Bright R . A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One. 2009; 4(6):e6032. PMC: 2698286. DOI: 10.1371/journal.pone.0006032. View

14.

Lam T, Wang J, Shen Y, Zhou B, Duan L, Cheung C . The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature. 2013; 502(7470):241-4. PMC: 3801098. DOI: 10.1038/nature12515. View

15.

Min J, Vogel L, Matsuoka Y, Lu B, Swayne D, Jin H . A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol. 2010; 84(22):11950-60. PMC: 2977864. DOI: 10.1128/JVI.01305-10. View

16.

Wilson N, Yang B, Morelli A, Koernig S, Yang A, Loeser S . ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol. 2011; 90(5):540-52. PMC: 3365289. DOI: 10.1038/icb.2011.71. View

17.

Belser J, Blixt O, Chen L, Pappas C, Maines T, Van Hoeven N . Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. Proc Natl Acad Sci U S A. 2008; 105(21):7558-63. PMC: 2396559. DOI: 10.1073/pnas.0801259105. View

18.

Katz J, Hancock K, Xu X . Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011; 9(6):669-83. DOI: 10.1586/eri.11.51. View

19.

Bright R, Carter D, Crevar C, Toapanta F, Steckbeck J, Cole K . Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008; 3(1):e1501. PMC: 2200794. DOI: 10.1371/journal.pone.0001501. View

20.

Maines T, Lu X, Erb S, Edwards L, Guarner J, Greer P . Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol. 2005; 79(18):11788-800. PMC: 1212624. DOI: 10.1128/JVI.79.18.11788-11800.2005. View